Prognostic impact of the combination of glucose transporter 1 and ATP citrate lyase in node-negative patients with non-small lung cancer

Highlights • Co-expression of GLUT1 plus ACLY in lung cancer (NSCLC) patients was studied. • GLUT1 plus ACLY status indicated worse overall survival than GLUT1 or ACLY alone. • Combined GLUT1 plus ACLY may be a prognostic marker in node-negative NSCLC patients.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Lung cancer (Amsterdam, Netherlands) Netherlands), 2015-06, Vol.88 (3), p.310-318
Hauptverfasser:	Osugi, Jun, Yamaura, Takumi, Muto, Satoshi, Okabe, Naoyuki, Matsumura, Yuki, Hoshino, Mika, Higuchi, Mitunori, Suzuki, Hiroyuki, Gotoh, Mitsukazu
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over ATP Citrate (pro-S)-Lyase - genetics ATP Citrate (pro-S)-Lyase - metabolism Biomarkers Carcinoma, Non-Small-Cell Lung - metabolism Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - pathology Female Gene Expression Glucose Transporter Type 1 - genetics Glucose Transporter Type 1 - metabolism Hematology, Oncology and Palliative Medicine Humans Immunohistochemistry Kaplan-Meier Estimate Lung Neoplasms - metabolism Lung Neoplasms - mortality Lung Neoplasms - pathology Lymphatic Metastasis Male Middle Aged Neoplasm Staging Prognosis Pulmonary/Respiratory Tumor Burden
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Co-expression of GLUT1 plus ACLY in lung cancer (NSCLC) patients was studied. • GLUT1 plus ACLY status indicated worse overall survival than GLUT1 or ACLY alone. • Combined GLUT1 plus ACLY may be a prognostic marker in node-negative NSCLC patients.
ISSN:	0169-5002 1872-8332
DOI:	10.1016/j.lungcan.2015.03.004